DD261095A5 - Verfahren zur herstellung von antiviralen kombinationen - Google Patents

Verfahren zur herstellung von antiviralen kombinationen Download PDF

Info

Publication number
DD261095A5
DD261095A5 DD87299551A DD29955187A DD261095A5 DD 261095 A5 DD261095 A5 DD 261095A5 DD 87299551 A DD87299551 A DD 87299551A DD 29955187 A DD29955187 A DD 29955187A DD 261095 A5 DD261095 A5 DD 261095A5
Authority
DD
German Democratic Republic
Prior art keywords
antiviral
compound
virus
nucleoside transport
combination
Prior art date
Application number
DD87299551A
Other languages
German (de)
English (en)
Inventor
Thomas P Zimmermann
Gerald Wolberg
Original Assignee
��������@��������@����������@���k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ��������@��������@����������@���k�� filed Critical ��������@��������@����������@���k��
Publication of DD261095A5 publication Critical patent/DD261095A5/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DD87299551A 1986-01-30 1987-01-29 Verfahren zur herstellung von antiviralen kombinationen DD261095A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868602346A GB8602346D0 (en) 1986-01-30 1986-01-30 Antiviral combinations

Publications (1)

Publication Number Publication Date
DD261095A5 true DD261095A5 (de) 1988-10-19

Family

ID=10592262

Family Applications (1)

Application Number Title Priority Date Filing Date
DD87299551A DD261095A5 (de) 1986-01-30 1987-01-29 Verfahren zur herstellung von antiviralen kombinationen

Country Status (20)

Country Link
US (1) US4897394A (fr)
EP (1) EP0235931B1 (fr)
JP (1) JPS62195337A (fr)
KR (1) KR870006900A (fr)
AT (1) ATE54414T1 (fr)
AU (1) AU590817B2 (fr)
CA (1) CA1283361C (fr)
DD (1) DD261095A5 (fr)
DE (1) DE3763597D1 (fr)
DK (1) DK46787A (fr)
ES (1) ES2031883T3 (fr)
FI (1) FI870377L (fr)
GB (1) GB8602346D0 (fr)
GR (1) GR3000638T3 (fr)
HU (1) HU198394B (fr)
IL (1) IL81422A0 (fr)
MC (1) MC1791A1 (fr)
PL (1) PL263871A1 (fr)
PT (1) PT84219B (fr)
ZA (1) ZA87667B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800081A (en) * 1984-04-18 1989-01-24 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
US4782065A (en) * 1984-04-18 1988-11-01 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
US4849412A (en) * 1986-06-05 1989-07-18 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
US5580571A (en) * 1991-10-15 1996-12-03 Hostetler; Karl Y. Nucleoside analogues
US5879700A (en) * 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
EP0684822B1 (fr) * 1993-02-19 2002-05-08 Southern Research Institute Analogues de deoxyguanosine carbocyclique pour le traitement d'infections virales
WO1994023723A1 (fr) * 1993-04-15 1994-10-27 New York University Agonistes de recepteur de l'adenosine favorisant la cicatrisation des lesions
WO1994026273A1 (fr) * 1993-05-12 1994-11-24 Hostetler Karl Y Derives d'acyclovir a usage topique
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
US6015573A (en) * 1993-05-12 2000-01-18 Hostetler; Karl Y. Nucleoside phosphate therapy for viral infection
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US5677308A (en) * 1996-12-19 1997-10-14 Lerner; A. Martin Method for alleviating spasmodic torticollis
US6399622B1 (en) 1997-02-18 2002-06-04 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US5872123A (en) 1997-02-18 1999-02-16 Lerner; A. Martin Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6537997B1 (en) 1997-02-18 2003-03-25 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
HRP20040421B1 (hr) * 2001-10-16 2013-05-31 Avanir Pharmaceuticals INHIBICIJA VIRUSA n-DOKOZANOLOM
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
US20140100238A1 (en) 2012-10-04 2014-04-10 Ohio State University Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
CN105079404A (zh) * 2015-09-07 2015-11-25 夏云强 一种治疗多重耐药菌所致感染性创面的中药外洗剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2080106B (en) * 1980-07-18 1984-03-07 Weelcome Foundation Ltd Acyclovin preparations
EP0108285B1 (fr) * 1982-10-14 1988-04-20 The Wellcome Foundation Limited Dérivés de purine antiviraux
GB8320308D0 (en) * 1983-07-28 1983-09-01 Wellcome Found Antiviral combinations
ES8801303A1 (es) * 1985-05-15 1987-12-16 Wellcome Found Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
DE3627024A1 (de) * 1985-09-24 1987-04-02 Hoechst Ag In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
MY101126A (en) * 1985-12-13 1991-07-31 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
HU198394B (en) 1989-10-30
KR870006900A (ko) 1987-08-13
PT84219A (en) 1987-02-01
CA1283361C (fr) 1991-04-23
FI870377A7 (fi) 1987-07-31
US4897394A (en) 1990-01-30
GR3000638T3 (en) 1991-09-27
ZA87667B (en) 1988-09-28
PT84219B (pt) 1989-07-31
AU6813587A (en) 1987-08-06
ES2031883T3 (es) 1993-01-01
EP0235931B1 (fr) 1990-07-11
EP0235931A1 (fr) 1987-09-09
DK46787D0 (da) 1987-01-29
IL81422A0 (en) 1987-08-31
JPS62195337A (ja) 1987-08-28
DE3763597D1 (de) 1990-08-16
ATE54414T1 (de) 1990-07-15
HUT42941A (en) 1987-09-28
DK46787A (da) 1987-07-31
MC1791A1 (fr) 1987-10-22
FI870377L (fi) 1987-07-31
GB8602346D0 (en) 1986-03-05
FI870377A0 (fi) 1987-01-29
AU590817B2 (en) 1989-11-16
PL263871A1 (en) 1988-05-12

Similar Documents

Publication Publication Date Title
DD261095A5 (de) Verfahren zur herstellung von antiviralen kombinationen
DE3650741T2 (de) Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
DE3687069T2 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DD264924A5 (de) Verfahren zur herstellung von pyrimidin-nucleosiden
DE3852531T2 (de) Nukleoside und nukleosid-analoge, pharmazeutische zusammensetzung und verfahren für die herstellung der bestandteile.
DE68906309T2 (de) Methode zur Behandlung von Kachexie und bestimmte dafür anzuwendende Verbindungen.
CH684310A5 (de) Substituierte Adeninderivate.
DE69333575T2 (de) Quinone-derivate zur verbesserung der zellulare bioenergie
US5405850A (en) Antiviral compositions consisting of acyclovir and a 2-acetyl pyridine derivative
DE69219482T2 (de) Mit einer einfach ungesättigten omega-9 C18 or C20 Fettsäure O-acylierte Nukleoside
DE4207363A1 (de) Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
US5021437A (en) 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl]thiocarbonohydrazone compound and salts thereof
EP0374096B1 (fr) Thérapie combinée utilisant le 2',5'-didéoxypurine nucléoside et inhibiteur de purine nucléoside-phosphorylase et ses compositions
DE3873207T2 (de) Antivirale therapie gegen hepatitis b mit 2',3'-didesoxynucleosiden.
DE3228060A1 (de) Verfahren zum behandeln von wuchernden hautkrankheiten
DE3408362C2 (de) Arzneimittel mit antineoplastischer Wirkung
DE3879575T2 (de) Alpha-Carotin zur Wachstumshemmung von Krebszellen.
DE2723451A1 (de) Polyribonucleotide, verfahren zu ihrer herstellung und ihre verwendung als oder in arzneimitteln
DE2538573A1 (de) Uridine und diese enthaltende pharmazeutische praeparate
DE3885090T2 (de) Zusammensetzung und verfahren zur behandlung von hepatitisvirusinfektionen unter verwendung von 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-ethyluracil.
DE60012961T2 (de) Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion
DD287406A5 (de) Therapeutische nucleoside
DD270656A5 (de) Verfahren zur herstellung eines aeusserlich anwendbaren, antiviralen, in der haut akkumulierenden pharmazeutischen praeparates
DE68905082T2 (de) Virushemmende pharmazeutische zusammensetzung.
DD289534A5 (de) Verfahren zur herstellung von antiviralen verbindungen